Next Article in Journal
Seasonal Changes in the Tetrodotoxin Content of the Flatworm Planocera multitentaculata
Next Article in Special Issue
Outdoor Cultivation of Marine Diatoms for Year-Round Production of Biofuels
Previous Article in Journal
Secondary Metabolites from Polar Organisms
Previous Article in Special Issue
A Saponification Method for Chlorophyll Removal from Microalgae Biomass as Oil Feedstock
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle
Mar. Drugs 2017, 15(3), 55; doi:10.3390/md15030055

Tuberatolide B Suppresses Cancer Progression by Promoting ROS-Mediated Inhibition of STAT3 Signaling

1
Jeju International Marine Science Center for Research & Education, Korea Institute of Ocean Science & Technology (KIOST), Jeju 63349, Korea
2
Laboratory of Clinical Biology and Pharmacogenomics, Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul 02247, Korea
3
Division of Food Bioscience, and Korea Nokyong Research Center, Konkuk University, Chungju 380-701, Korea
*
Author to whom correspondence should be addressed.
Academic Editor: Paul Long
Received: 29 December 2016 / Revised: 6 February 2017 / Accepted: 17 February 2017 / Published: 25 February 2017
(This article belongs to the Special Issue Advances and New Perspectives in Marine Biotechnology II 2016)
View Full-Text   |   Download PDF [3162 KB, uploaded 25 February 2017]   |  

Abstract

Tuberatolide B (TTB, C27H34O4) is a diastereomeric meroterpenoid isolated from the Korean marine algae Sargassum macrocarpum. However, the anticancer effects of TTB remain unknown. In this study, we demonstrate that TTB inhibits tumor growth in breast, lung, colon, prostate, and cervical cancer cells. To examine the mechanism by which TTB suppresses cell growth, we determined the effect of TTB on apoptosis, ROS generation, DNA damage, and signal transduction. TTB induced ROS production in MDA-MB-231, A549, and HCT116 cells. Moreover, TTB enhanced DNA damage by inducing γH2AX foci formation and the phosphorylation of DNA damage-related proteins such as Chk2 and H2AX. Furthermore, TTB selectively inhibited STAT3 activation, which resulted in a reduction in cyclin D1, MMP-9, survivin, VEGF, and IL-6. In addition, TTB-induced ROS generation caused STAT3 inhibition, DNA damage, and apoptotic cell death. Therefore, TTB suppresses cancer progression by promoting ROS-mediated inhibition of STAT3 signaling, suggesting that TTB is useful for the treatment of cancer. View Full-Text
Keywords: tuberatolide B; cancer; STAT3; ROS; DNA damage tuberatolide B; cancer; STAT3; ROS; DNA damage
Figures

Figure 1a

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Choi, Y.K.; Kim, J.; Lee, K.M.; Choi, Y.-J.; Ye, B.-R.; Kim, M.-S.; Ko, S.-G.; Lee, S.-H.; Kang, D.-H.; Heo, S.-J. Tuberatolide B Suppresses Cancer Progression by Promoting ROS-Mediated Inhibition of STAT3 Signaling. Mar. Drugs 2017, 15, 55.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top